Olopatadine Eye Drops and Allergy Skin Testing

Vanderbilt University Medical Center

Status: Completed

Conditions: Allergic Conjunctivitis; Allergic Rhinitis

Treatments: Drug: olopatadine; Drug: placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT00775658

071260

Details and patient eligibility

About

Use of olopatadine ophthalmic solution (eye drops) will decrease allergy skin test reactivity.

Enrollment: 24 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults aged 18 to 75 years
• Healthy volunteers (no major illnesses or active symptoms)

Exclusion criteria

• Known allergy or hypersensitivity to the drugs or components
• Pregnant or nursing women
• Women wishing to become pregnant during the study's duration
• Use of topical or oral medications with antihistaminic activity for 14 days proceeding randomization
• Dermatographism as evidenced on skin testing on visit 1
• Chronic urticaria active within the past 6 months
• Severe hypertension
• Psychiatric diagnoses which could potentially affect medication compliance, such as schizophrenia or delusional disorders, as determined by the investigator obtaining informed consent and based on the subject's past medical history
• Inability to provide informed consent

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

24 participants in 2 patient groups

olopatadine then placebo

Active Comparator group

Description:

participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days

Treatment:

Drug: placebo

Drug: olopatadine

placebo then olopatadine

Active Comparator group

Description:

participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days

Treatment:

Drug: placebo

Drug: olopatadine